All In Biotech

Drug Trial Radar · NCT07008469

Global Open-Label Extension Study of Del-desiran for the Treatment of DM1

A Global Phase 3 Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Intravenous AOC 1001 for the Treatment of Myotonic Dystrophy Type 1

Last checked: Nov 20, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

199

Planned (sponsor's estimate)

Start

Jun 26, 2025

Primary completion

Oct 2030

Study completion Oct 2030

Sponsor

Lead sponsor
Avidity Biosciences, Inc.Industry
Sponsor type
Industry
First posted
Jun 6, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Global Phase 3 Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Intravenous Delpacibart Etedesiran (abbreviated del-desiran, formerly AOC 1001) for the Treatment of Myotonic Dystrophy Type 1

Conditions

  • Myotonic Dystrophy Type 1
  • DM1
  • Myotonic Dystrophy
  • Myotonia
  • Myotonic Dystrophy 1
  • Myotonic Disorders
  • Steinert Myotonic Dystrophy
  • Steinert Disease

Interventions

  • Del-desiran (AOC 1001)Drug

    Del-desiran will be administered by intravenous (IV) infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. TEAEsTime frame: From enrollment to the end of treatment at 4 years

Locations

35 sites in 10 countries. Site status is shown where the registry gives one.

  • University of California, Los Angeles (UCLA)

    Los Angeles, California

  • Stanford University

    Stanford, California

  • University of Colorado

    Denver, Colorado

  • University of Florida

    Gainesville, Florida

  • University Research Center of South Florida

    Tampa, Florida

  • Indiana University (IU)

    Indianapolis, Indiana

  • Kansas University Medical Center

    Kansas City, Kansas

  • Kennedy Krieger Institute

    Baltimore, Maryland

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • University of Minnesota

    Minneapolis, Minnesota

  • University of Rochester Medical Center

    Rochester, New York

  • Duke University Medical Center

    Durham, North Carolina

  • Wake Forest

    Winston-Salem, North Carolina

  • University of Cincinnati Gardner Neuroscience Institute

    Cincinnati, Ohio

  • Ohio State University

    Columbus, Ohio

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Houston Methodist Neurological Institute

    Houston, Texas

  • Virginia Commonwealth University

    Richmond, Virginia

  • University of Washington

    Seattle, Washington

  • The Ottawa Hospital

    Ottawa, Ontario, Canada

  • Montreal Neurological Institute

    Montreal, Quebec, Canada

  • Aarhus University Hospital

    Aarhus, Denmark

  • Rigshospitalet

    Copenhagen, Denmark

  • AP-HP Hopital Pitie-Salpetriere

    Paris, France

  • Klinikum der Ludwig-Maximilians-Universitaet Muenchen

    München, Germany

  • Fondazione Serena Onlus - Centro Clinico NeMO Milano

    Milan, Italy

  • National Hospital Organization Osaka Toneyama Medical Center

    Osaka, Japan

  • Osaka University Hospital

    Osaka, Japan

  • National Center of Neurology and Psychiatry

    Tokyo, Japan

  • Aomori Hospital

    Aomori, Aomori, Japan

  • Maastricht University Medical Center

    Maastricht, Netherlands

  • Stichting Radboud Universitair Medisch Centrum

    Nijmegen, Netherlands

  • Hospital Universitario Donostia

    San Sebastián, Spain

  • University College London Hospital

    London, United Kingdom

  • St. Georges University Hospitals NHS Foundation Trust

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.